The cloning and characterization of the common fragile site (CFS) FRA6E (6q26) identified Parkin, the gene involved in the pathogenesis of many cases of juvenile, early-onset and, rarely, late-onset Parkinson's disease, as the third large gene to be localized within a large CFS. Initial analyses of Parkin indicated that in addition to playing a role in Parkinson's disease, it might also be involved in the development and/or progression of ovarian cancer. These analyses also indicated striking similarities among the large CFS-locus genes: fragile histidine triad gene (FHIT; 3p14.2), WW domain-containing oxidoreductase gene (WWOX; 16q23), and Parkin (6q26). Analyses of FHIT and WWOX in a variety of different cancer types have identified the presence of alternative transcripts with whole exon deletions. Interestingly, various whole exon duplications and deletions have been identified for Parkin in juvenile and early-onset Parkinson's patients. Therefore, we performed mutational/exon rearrangement analysis of Parkin in ovarian cancer cell lines and primary tumors. Four (66.7%) cell lines and four (18.2%) primary tumors were identified as being heterozygous for the duplication or deletion of a Parkin exon. Additionally, three of 23 (13.0%) nonovarian tumorderived cell lines were also identified as having a duplication or deletion of one or more Parkin exons. Analysis of Parkin protein expression with antibodies revealed that most of the ovarian cancer cell lines and primary tumors had diminished or absent Parkin expression. While functional analyses have not yet been performed for Parkin, these data suggest that like FHIT and WWOX, Parkin may represent a tumor suppressor gene.
Introduction
Parkinson's disease is a neurodegenerative disorder characterized by tremors, rigidity, and bradykinesia.
While the peak age of onset is approximately 60 years of age, there are cases of early-onset (o50 years of age) and even juvenile (o20 years of age) Parkinson's disease. Linkage studies of autosomal recessive juvenile Parkinson's (ARJP) patients and their families identified the gene Parkin as a potential target for mutation in these patients . Mutational analysis of ARJP patients has revealed the presence of various intragenic deletions/duplications and point mutations in Parkin Lu¨cking et al., 2000; Hedrich et al., 2001 Hedrich et al., , 2002 Hoenicka et al., 2002; Kann et al., 2002; Nichols et al., 2002; West et al., 2002) . Subsequently, these mutations have been demonstrated to be responsible for the manifestation of juvenile, earlyonset, and sometimes late-onset Parkinson's disease (Imai et al., 2000; Tanaka et al., 2001; Kahns et al., 2002) .
The recent cloning and characterization of the common fragile site (CFS) FRA6E (6q26), the third most frequently observed CFS in the human population, has determined that Parkin localizes within the FRA6E region of instability (Denison et al., 2003) . CFSs are chromosomal loci that are susceptible to forming gaps and/or breaks when cultured in the presence of chemicals such as bromodeoxyuridine, 5-azacytidine, and aphidicolin. Characterization of FRA6E determined that the region of aphidicolin-induced instability extended approximately 3.6 Mb and that Parkin spanned the distal half of this region. The center (most unstable region) of FRA6E was determined to localize between exons 2 and 8 of Parkin, but was not located at the physical center of the CFS region. Loss of heterozygosity (LOH) analysis of 20 primary ovarian tumors using markers mapping to the FRA6E region identified a significantly high frequency of LOH at D6S1599 and D6S305, two markers that localize within introns 2 and 6, respectively, of Parkin. RT-PCR analysis of Parkin determined that Parkin expression was downregulated in over half of the primary ovarian tumors analysed. These data suggested that in addition to playing a role in Parkinson's disease, Parkin may also be involved in the development and/or progression of ovarian cancer (Denison et al., 2003) .
Parkin is the third large gene (1. 5 Mb) to be identified in a region of genomic instability; fragile histidine triad (FHIT) and WW domain-containing oxidoreductase (WWOX), located within the two most active CFSs FRA3B (FHIT) and FRA16D (WWOX), have been estimated at 1.4 and 1.0 Mb, respectively. FHIT and WWOX have been shown to independently suppress tumor growth and as a result both have been classified as putative tumor suppressor genes (Ohta et al., 1996; Siprashvili et al., 1997; Bednarek et al., 2000) . Preliminary analyses of Parkin indicate that like FHIT and WWOX, Parkin may represent a tumor suppressor gene. Analyses of FHIT and WWOX in various cancer types have identified the presence of alternative transcripts in both primary tumors and tumor-derived cell lines (Druck et al., 1997; Bednarek et al., 2001; Roz et al., 2002; Denison et al., 2003) . Parkin alternative transcripts have also been identified in both ovarian tumorderived cell lines and primary tumors (Denison et al., 2003) .
The focus of this study was to investigate Parkin as a potential mutational target in cancer. We confirm data reported by Denison et al. (2003) that Parkin is downregulated in ovarian cancer, and analyse both ovarian tumors and cell lines for the presence of the Parkin protein. Western blot analysis of seven primary ovarian tumors and six ovarian tumor-derived cell lines identified five primary tumors and four cell lines as exhibiting decreased or the complete absence of Parkin protein expression. We also report alternative Parkin transcripts in both ovarian cell lines and primary tumors. Four of seven ovarian cell lines and four of 22 primary ovarian tumors were identified with a duplication/deletion of one or more Parkin exons. Additionally, RT-PCR of Parkin on a panel of cell lines derived from breast, cervical, kidney, and prostate cancers was performed to determine if Parkin is genetically altered in cancer types other than ovarian cancer. Heterozygous whole exon duplications and deletions were detected in both breast and cervical cancer cell lines. While in most cases a normal Parkin transcript is present along with the alternative transcript, we demonstrate in some instances the complete absence of Parkin protein in these cell lines. These data not only indicate that Parkin may be genetically altered in a variety of different tumor types, but also demonstrate striking similarities among the CFS genes FHIT, WWOX, and Parkin. As a result, these data suggest that like FHIT and WWOX, Parkin may represent a putative tumor suppressor gene.
Results

Homozygous duplication/deletion (HD) screening
HD analysis was performed on a genomic DNA panel consisting of six ovarian tumor-derived cell lines and 22 primary ovarian tumors for each of the 12 exons of Parkin. Each primer set was run individually on the panel and then run in a multiplex reaction with primers unique to one of two markers mapping to the p-arm of chromosome 6 (WI-6213 and WI-7023) for confirmation (Table 1 ; data not shown). Both WI-6213 and WI-7023 markers were initially tested on the DNA panel to confirm the presence of these two markers in each DNA sample examined (data not shown). None of the ovarian cell lines or primary tumors examined exhibited an HD for any of the exons analysed (data not shown).
Heterozygous duplication/deletion (HD) screening
Hd mapping was performed using the quantitative duplex PCR technique described by Hedrich et al. (2001) . Hedrich et al. (2001) used real-time PCR to determine the gene dosage ratio of the Parkin gene as compared to the reference gene beta globin (HBB) in order to identify heterozygous deletions and/or duplica- Primers used in a study by Denison et al. (2003) Alterations in the common fragile site SR Denison et al tions of whole exons of Parkin in a subset of ARJP patients. Gene dosage analysis of the six cell lines identified four cell lines (OV202, OV177, OV207, and OVCAR5) with heterozygous Parkin mutations. Of the four cell lines, two (OV202 and OV107) were identified as having an HD of one or more Parkin exons. OV202 exhibited an HD for exon 1 (Parkin/HBB ratio of 0.8; Table 2 ). OV177, however, exhibited HDs for both exons 1 and 4 (Parkin/HBB ratios of 0.7 and 0.9, respectively; Table 2 ). Alternatively, OV207 and OV-CAR5 were identified as having heterozygous duplications of Parkin exons. OVCAR5 was identified as having a duplication of exon 12 (Parkin/HBB ratio of 1.07; Table 2 ) while OV207 was identified as having a duplication of exons 5, 8, and 12 (Parkin/HBB ratios of 0.7, 0.95, and 0.74, respectively).
Alternative transcript screening
In a previous article, we screened 22 primary ovarian tumors using Parkin-specific primers designed to amplify exons 1-6 and 5-12 of Parkin. We subsequently identified eight of the 22 different ovarian tumors with possible Parkin alternative transcripts (Denison et al., 2003) . In this study, we extracted the observed alternative bands and sequenced them to demonstrate that the band was derived from Parkin. Sequencing of the alternative PCR products determined that four of the 22 primary ovarian tumors (354T, 526T, 103T, and 270T) did exhibit alternative transcripts. The remaining four alternative bands that were observed were not derived from Parkin sequence. Tumors 354T, 103T, and 270T all exhibited a heterozygous deletion of exon 4. Alternatively, 526T exhibited a heterozygous duplication of exon 2. For all four tumors, these alternative transcripts were in the presence of a normal Parkin transcript (Denison et al., 2003) . Using the same Parkinspecific primers, we also screened 22 nonovarian tumorderived cell lines (nine cervical, six pancreatic, four prostate, and three renal) for the presence of Parkin alternative transcripts (Table 1, Figure 1 ). Only six of the 22 cell lines, two cervical (SW756 and SiHa) and four prostate (LNCAP, LNCAPÀ, DU145, and PC3), exhibited normal full-length Parkin transcripts (Figure 1 , Table 3 ). The remaining 16 cell lines (72.7%) were identified as lacking a normal full-length Parkin transcript (i.e. did not produce a full-length PCR product when cDNA was amplified using either the 1-6 or 5-12 Parkin primer sets) (Figure 1 , Table 3 ). In some instances, neither primer set produced a PCR product (C-41, CFPAC-1, BXPC-3, and CAPAN-2), indicating the complete absence of Parkin expression in those cell lines. The remaining 12 cell lines were identified as having truncated Parkin transcripts ( Figure 1 , Table 3 Table 3 ). Two cervical (C33A and ME180) and two pancreatic cell lines (CAPAN-1 and CAPAN-2) were identified as having heterozygous Heterozygous duplication range based on copy number.
e Numbers in bold indicate either the duplication or deletion of that particular exon
Prostate ( Table 3 ). ME180 was identified as exhibiting a heterozygous deletion of exon 4, C33A exhibited a heterozygous deletion of both exons 3 and 4, and CAPAN-1 and CAPAN-2 both exhibited a heterozygous deletion of exon 5 ( Figure 1 , Table 3 ). None of these cell lines produced a normal fulllength Parkin transcript.
Western blot analysis
To verify if Parkin expression was altered in primary ovarian tumors and tumor-derived cell lines, we performed Western blot analysis on seven primary ovarian tumors (OV111, OV270, OV465, OV470, OV491, OV714, and OV854) and six ovarian tumorderived cell lines (OV167, OV177, OV202, OV207, SKOV3, and OVCAR5) with the AB5112 PARK2 antibody produced by Chemicon (Temecula, CA, USA). This antibody corresponds to amino-acid residues 303-523 of Parkin and yields a 44-52 kDa band in normal brain tissue. However, this antibody had never been tested on any tissue other than brain. Horowitz et al. (2001) have shown that the size of the Parkin protein can vary between tissue types. Therefore, the antibody was initially tested on protein extracted from normal ovarian surface epithelium (OVSE) to determine the size of the expected protein and to confirm the expression level of Parkin protein in the normal surface epithelium of the ovary. Contrary to what has been observed using this antibody in normal brain tissue, Western blot analysis of OVSE using the Chemicon antibody produced a single Parkin band at 55-60 kDa. Western blot analysis of the primary ovarian tumors revealed that four of the six cell lines (66.7%) and five of the seven tumors (71.4%) had either decreased or complete absence of Parkin expression. Compared to normal Parkin expression levels, the cell lines OV167, OV177, OV202, and OV207 exhibited decreased levels of Parkin expression. SKOV3 and OVCAR5 exhibited normal Parkin expression levels. As for the primary ovarian tumors, a downregulation of Parkin expression was observed for OV270, OV470, and OV491, while a complete absence of Parkin expression was observed in OV111 and OV465 (Figure 2 ). OV714 and OV854 exhibited normal expression levels of Parkin (Figure 2 ).
Discussion
CFSs are highly unstable genomic regions that are apparently present in all individuals. While they are characterized utilizing an in vitro assay of chromosomal decondensation/breakage induced by inhibitors of DNA replication, their in vivo significance is that they predispose chromosomes to breakage and rearrangement especially in developing cancer cells Smith et al., 1998; Sutherland et al., 1998) . CFSs have also been shown to be important in the process of gene amplification (Hellman et al., 2002) .
The four most active of the CFS regions are FRA3B (3p14.2), FRA16D (16q23.2), FRAXB (Xp22.31), and FRA6E (6q26). Three of these regions, FRA3B, FRA16D, and FRA6E, are consistently deleted during the development of many different cancers including Figure 2 Western blot analysis of six ovarian tumor-derived cell lines (OV167, OV177, ON202, OV207, SKOV3, and OVCAR5) and seven primary ovarian tumors (OV470, OV491, OV854, OV270, OV111, and OV465). A Parkin polyclonal antibody and a corresponding control actin antibody were used to screen the tumors for the expression levels of Parkin protein. Normal OVSE was also analysed to determine the normal levels of Parkin protein expression in the OVSE ovarian cancer. These three regions share many similarities. Instability within each CFS region extends from 2.0 to 4.5 Mb (Krummel et al., 2000; Becker et al., 2002; Denison et al., 2003) . The 'center' of each region of instability, where the majority of decondensation/breakage occurs, is only 500 kb in size and does not necessarily correspond with the physical center of the CFS region (Becker et al., 2002; Denison et al., 2003) . Spanning the 'center' of these unstable regions are extremely large genes that encode relatively small final processed transcripts. FRA3B and FRA16D also appear to be highly conserved between humans and mice. Both FRA3B and FRA16D represent fragile regions in the mouse, Fra14A2 and Fra8E1, respectively (Shiraishi et al., 2001; Krummel et al., 2002) . Additionally, the mouse orthologs of FHIT and WWOX (Fhit and Wox1) also appear to have been conserved together through evolution (Shiraishi et al., 2001; Krummel et al., 2002) . The FRAXB region is distinct from the other three highly active CFS regions, as instability within this CFS region extends for only 500 kb (Arlt et al., 2002) . In addition, FRAXB has been shown to contain several smaller genes including the 105 and 146 kb GS1 and STS genes, but not extremely large genes (Arlt et al., 2002) . FRAXB is also derived from a chromosomal region that is not consistently deleted in any tumor type.
An examination of multiple tumor types reveals that deletions and alterations in FHIT and WWOX are commonly observed in cancer (Druck et al., 1997; Bednarek et al., 2001) . However, these genes rarely contain point mutations and only a single report of a point mutation within FHIT exons has been described (Gamma et al., 1997). Corbin et al. (2002) examined FHIT/FRA3B homologues from cancer-derived cell lines using somatic cell hybrids and found that there were multiple heterozygous deletions even within one cell line, suggesting that the large deletions result in inactivation of both FHIT alleles. Since the genomic regions spanning these two large genes are so large and unstable, there has not been a comprehensive analysis of genomic alterations in these regions in cancer. Analysis of the proteins encoded by these CFS regions, however, has determined that expression of these genes is frequently lost in many tumor types including ovarian cancer (Druck et al., 1998; Bednarek et al., 2001) .
While CFSs have been proposed to play a causal role in tumorigenesis and/or cancer progression, it has been unclear as to whether or not the chromosomal fragility at these loci is the consequence or cause of tumorigenicity. The development and/or progression of cancer may merely cause increased instability within the CFS regions resulting in the loss of expression (LOE) of genes localizing within the CFSs due to a bystander effect. Alternatively, these genes may in fact play an active role in cancer progression. Although the large CFS-locus genes do not appear to be traditional mutational targets like other tumor suppressor genes, there is evidence to suggest that they functionally act as tumor suppressors. Replacement of FHIT or WWOX into cancer cells that do not produce them frequently results in the inhibition of tumor growth or the induction of apoptosis (Druck et al., 1998; Bednarek et al., 2001) . FHIT À/À mice are much more susceptible to tumor formation upon exposure to the mutagen NMBA, but this can be inhibited by replacement of FHIT into these mice (Ishii et al., 2001) .
Mutations in Parkin have been demonstrated to be responsible for the pathogenesis of juvenile, early-onset, and even late-onset Parkinson's disease. These mutations consist of point mutations, small deletions, exonic duplications and deletions, and intron-exonic deletions. All these result in amino-acid substitutions or the premature truncation of the Parkin protein. However, in contrast to most other disease-causing genes, the majority of Parkin mutations consist primarily of exonic duplications and deletions. Alterations have been documented through the Parkin coding sequence, but the majority of them localize between exons 2 and 8 of Parkin Lu¨cking et al., 2000; Hedrich et al., 2001 Hedrich et al., , 2002 Hoenicka et al., 2002; Kann et al., 2002; Nichols et al., 2002; West et al., 2002) .
To further investigate potential alterations in Parkin in ovarian cancer, we utilized a screening method developed by Hedrich et al. (2001) , which they employed to search for heterozygous and homozygous deletions of the Parkin gene in ARJP patients. This method allows for the screening of all 12 Parkin exons by means of realtime quantitative PCR (Hedrich et al., 2001 ) and for the identification of duplications and deletions that were potentially undetectable using conventional PCR. Hedrich et al. (2001) demonstrated that their technique was more sensitive than conventional screening at detecting mutations in Parkin. In the screening of 21 ARJP patients for mutations, single-strand conformational polymorphisms and sequence analysis detected only three different mutations, while the method developed by Hedrich et al. (2001) detected seven. We used this quantitative duplex PCR technique to analyse six ovarian cancer cell lines for Parkin mutations. However, due to the karyotypic variation frequently observed in both primary tumors and tumor-derived cell lines, the ratios used for the identification of alterations had to be modified to reflect accurately the changes in the gene dosage ratio of Parkin to HBB that could be attributed to aneuploidy. We therefore performed fluorescence in situ hybridization (FISH) on all six tumor-derived cell lines to determine the ratio of observed hybridization signals of Parkin to HBB. Based on these ratios, the normal and aberrant gene dosage values (ranges) for each individual cell line were recalculated and used for the identification of deletions, as well as duplication of Parkin exons (Table 2) . Screening of the six ovarian cancer cell lines revealed that four were heterozygous for Parkin deletions. As was shown with ARJP patients, the observed large deletions identified in the ovarian cancer cell lines localized throughout the Parkin gene. Two cell lines (OV202 and OV177) were found to have whole exon deletions (exon 1 in OV202 and exons 1 and 4 in OV177). In the case of OV177, it is likely that both exons 1 and 4 are deleted from the same allele, as previous RT-PCR analysis of OV177 revealed the presence of a normal Parkin transcript (Denison et al., 2003) . Two other ovarian cancer cell lines, OV207 and OVCAR5, were identified as having whole exon duplications (exon 5, 8, and 12 for OV207 and exon 12 for OVCAR5). The presence of whole exon duplications/deletions in the Parkin gene is consistent with this gene localizing to a region of instability and indicates that instability in this region may promote the rearrangement of the Parkin gene in both ARJP and during cancer development.
While analyses of FRA3B, FRA16D, and FRA6E demonstrate that each has been associated with a region of high LOH and LOE for genes mapping within them, functional studies have focused primarily on FHIT and WWOX (Ohta et al., 1996; Druck et al., 1998; Le Beau et al., 1998; Bednarek et al., 2000 Bednarek et al., , 2001 Krummel et al., 2000; Mangelsdorf et al., 2000; Paige et al., 2000; Arlt et al., 2002; Denison et al., 2003) . Alternative transcripts, typically consisting of whole exon deletions, have been identified for FHIT and WWOX in both tumor-derived cell lines and primary tumors (Druck et al., 1998; Bednarek et al., 2001) . These types of alternative transcripts have also been identified for Parkin in several different cancer types (Denison et al., 2003; this study) . In this study, heterozygous whole exon duplications and deletions were confirmed in both primary ovarian tumors and tumor-derived cell lines (discussed previously). Of the 22 primary tumors analysed for alternative transcripts, four (18.2%) were identified as having a duplication or deletion of a Parkin exon. Three of the four tumors exhibited deletions for exon 4 (103T, 354T, and 270T) while the remaining tumor (526T) exhibited a duplication of exon 2. Additionally, 22 nonovarian tumor-derived cell lines (nine cervical, six pancreatic, four prostate, and three renal cell lines) were also analysed for the presence of alternative transcripts. Of the 22 cell lines analysed, 16 (72.7%) did not produce a normal full-length Parkin transcript (Figure 1, Table 3 ); two cervical (SW756 and SiHa) and four prostate cell lines (LNCAP, LNCAPÀ, DU145, and PC3) exhibited normal full-length Parkin transcripts (Figure 1, Table 3 ). Four of the 16 cell lines (C-41, CFPAC-1, BXPC-3, and CAPAN-2) were identified as completely lacking Parkin expression. The remaining 12 cell lines were identified as producing a truncated Parkin transcript (Figure 1, Table 3 ). HeLa, MD751, Caski, HT-3, and C-41 did not produce a normal 5 0 -end transcript when cDNA was amplified using primers specific to exons 1 and 6 of Parkin. ME-180, ASPC-1, MIA, CAPAN-1, HTB-45, HTB-49, and CRL-1933 did not produce a normal 3 0 -end transcript when cDNA was amplified using primers specific to exons 5 and 12 of Parkin.
A recent article by Cesari et al. (2003) has also identified Parkin alterations in ovarian and lung cancers. They performed mutational analysis of 20 ovarian tumors and identified three (15.0%) with truncating deletions. Cesari et al. (2003) also identified two lung adenocarcinoma cell lines with homozygous deletions of exon 2. Interestingly, the vast majority of the cell lines and primary tumors identified as having a Parkin mutation are the result of the duplication or deletion of an exon between exons 2 and 8, the center of the FRA6E region.
Parkin is therefore the first CFS gene that is involved in a disease other than cancer. As Parkin is a mutational target in ARJP patients, most of the functional studies of Parkin have focused on its role in neurodegeneration. Parkin functions as an E3 ubiquitin ligase that facilitates the degradation of misfolded and unfolded proteins through the proteasomal system. As part of the ubiquitin proteosome pathway (UPP), Parkin can protect neurons from diverse cellular insults, including alpha-synuclein toxicity, proteosomal dysfunction, Pael-R accumulation and kainite-induced excitotoxicitity (Zhang et al., 2000; Petrucelli et al., 2002; Darios et al., 2003; Staropoli et al., 2003) . Parkin also plays a central role in maintaining dopaminergic neuronal integrity (Feany and Pallanck, 2003) . Parkin has been shown to interact with actin (Huynh et al., 2000) , but nothing is known as to how loss of Parkin could contribute to cancer development.
We have therefore found that the third large CFS gene Parkin bears many similarities to FHIT and WWOX. Our data combined with that of Cesari et al. (2003) suggest that Parkin is a candidate tumor suppressor gene. Large structural deletions within the center of the FRA6E region are observed in ovarian cancers and also in lung and other cancers. We have demonstrated that loss of Parkin expression is frequently observed in ovarian and other cancers, and Cesari et al. (2003) also detected decreased Parkin protein in breast and ovarian tumors and cell lines. We are currently functionally characterizing Parkin to determine what role it plays in the normal cell and how loss of Parkin function might contribute to the development of cancer.
What role might Parkin play in the development and/ or progression of cancer? If loss of Parkin promoted tumorigenesis, there would be an increased incidence of cancer in juvenile and early-onset Parkinson's patients with Parkin mutations. Alternatively, Parkin may be involved in the processes of angiogenesis and/or metastasis. Patients with Parkin mutations would therefore only have an increased susceptibility for cancer progression and not tumorigenesis. In that instance, one would not expect to see an increased incidence of cancer in juvenile and/or early-onset Parkinson's patients. Currently, however, there are no data of the incidence of cancer in these patients. The frequency of Parkinson's patients with Parkin mutations is in fact quite low; therefore, it would be difficult to determine if these patients do have a higher incidence of cancer. Therefore, functional studies of Parkin will be necessary to further elucidate Parkin's potential role in cancer development.
Materials and methods
HD screening
Primers unique for all 12 exons were synthesized by the Mayo Foundation Molecular Core Facility (Rochester, MN, USA) and tested on a DNA panel consisting of genomic DNA isolated from seven ovarian tumor-derived cell lines and 22 primary tumors (Table 1) . Genomic DNA was isolated from the cell lines and the primary tumors using standard phenolchloroform methods. The PCR mix (12.5 ml reaction volume) contained 20 ng of genomic DNA, 1 Â PCR buffer (as supplied with enzyme), 200 mM dNTPs, 200 mM forward primer, 200 mM reverse primer, and 0.1 U Taq polymerase (Promega, Madison, WI, USA). The conditions for amplification were: 951C for 3 min, then 35 cycles of 951C for 30 s, 55-611C for 30 s, and 721C for 30 s with a final extension of 721C for 10 min. All reactions were performed in duplicate to validate results. Additionally, any identified exonic HD was re-evaluated by using the exon-specific primers in a multiplex reaction, with specific primers for one of two markers localizing to the p-arm of chromosome 6 (WI-6213 and WI-7023; Table 1 ). These multiplex reactions were also run in duplicate to ensure reliability of the PCR results.
Hd screening
Owing to the potential normal tissue contamination of the primary tumors, only the ovarian tumor-derived cell lines were analysed for possible HDs. Gene dosage analysis was performed by means of a quantitative duplex PCR assay of all 12 exons of Parkin on the LightCycler (Roche Diagnostics, Indianapolis, IN, USA) using the fluorescence resonance energy transfer technique in a quantitative duplex PCR assay. In brief, the HBB gene was coamplified with each individual Parkin exon and served as an internal standard. For primers, probes, and details of the method, see Hedrich et al. (2001) . The following reagents were used for amplification in a 10 ml reaction: 1 ml Hybridization FastStart Mix (Roche Diagnostics, Indianapolis, IN, USA), 2-4.5 mM MgCl 2 , 0.2 mM of each hybridization probes (one pair of 3 0 -fluorescein and 5 0 -LightCycler Red 640 for Parkin), 0.5-1.0 mM of each primer, and 1-15 ng of DNA. A standard curve was generated using human genomic DNA (Roche Diagnostics, Indianapolis, IN, USA) in concentrations of 5, 1.25, and 0.3125 ng/ml, respectively. All standards (and samples) were amplified in duplicate, followed by calculation of a regression curve, based on which sample concentrations were inferred and accepted only when within the range of the standard templates. All detected gene dosage variations were confirmed at least twice. Hedrich et al. (2001) determined that the normal gene dosage ratio for any Parkin exon as compared to HBB ranged from 0.8 to 1.2. Dosage values of less than 0.4, from 0.4 to 0.6, and 1.3 to 1.7 were identified as representing a homozygous deletion, heterozygous deletion, and a heterozygous duplication, respectively, for that particular Parkin exon (Hedrich et al., 2001) . These ratios/ranges were based on the assumption that a normal ratio of Parkin to HBB would equal 1.0720%, whereas a deletion would be reflected by a ratio of 0.5720%. However, they did not define a heterozygous duplication as 1.2-1.8 because it would not allow for a clear differentiation between a 'high normal' and a 'low duplication' ratio. The use of a ratio of 1.3-1.7 allowed for a more conservative estimate of heterozygous duplications.
These ratios, however, specifically reflect the gene dosage levels for karyotypically normal individuals. Karyotypic analysis of primary tumors as well as tumor-derived cell lines has demonstrated that most cancers are aneuploid with variation in both chromosome number and structure (Knudson, 2001 ). Therefore, we modified the gene dosage ratios described by Hedrich et al. (2001) to reflect accurately the changes in the gene dosage ratio of Parkin to HBB that could be attributed to the observed karyotypic variation observed among the cell lines. We performed FISH using two bacterial artificial chromosomes (BACs), one containing a portion (exons 3 and 4) of Parkin and the other containing a portion of HBB, and hybridized them to interphase nuclei obtained from each cell line (Figure 3) . A total of 50 interphases were analysed for each of the six different cell lines to determine the average number of Parkin and HBB hybridization signals observed per metaphase. Based on the average number of signals per metaphase, the ratio of observed hybridization signals of Parkin to HBB was determined for each individual cell line (Figure 3, Table 2 ). This ratio was then used to calculate the expected normal and aberrant gene dosage values (ranges) for each cell line. For example, the ratio of observed hybridization signals of Parkin to HBB for the cell line OV177 was determined to be 1.47. Therefore, the expected range values for OV177 should be 1.47 times greater than that of a karyotypically normal cell. As a result, the normal range for OV177 should be 1.2-1.8 (versus 0.8-1.2) and the ranges for a heterozygous deletion and heterozygous duplication should be 0.6-0.9 and 2.1-2.4, respectively. The modified values for each cell line are provided in Table 2 .
Fluorescence in situ hybridization
Metaphase/interphase preparations were obtained from ovarian tumor-derived cell lines grown in a T75 tissue culture flask under the appropriate tissue culture conditions. Cultures were incubated at 371C in 5% CO 2 until the flask reached confluency. Cell harvest and metaphase preparations followed routine cytogenetic techniques.
Three different BACs were used to determine (1) whether any of the six ovarian cell lines exhibited aneuploidy for chromosome 6 and (2) the Parkin dosage levels for each particular cell line. These three probes included a centromere probe specific to chromosome 6, RP-1 179P19 (a BAC containing a portion of exons 3 and 4 of Parkin), and CTD-2643I7 (a BAC containing a portion of HBB).
For clones 179P19 and 2643I7, 1 mg of purified DNA was labeled with biotin-16-dUTP (Boehringer/Roche, Indianapolis, IN, USA) by nick translation, precipitated and hybridized to the interphase chromosomes according to the protocol described by Verma and Babu (1995) . The chromosome 6 centromere probe was prelabeled with a cyan fluorochrome and therefore did not require labeling with biotin-16-dUTP and could be directly hybridized to interphase chromosomes. Probe detection for the remaining BACs followed minor modifications of the manufacturer's protocols (Ventana Medical Systems, Tucson, AZ, USA). Chromosomes were counterstained with DAPI. Photomicroscopy was performed using a Zeiss Axioplan 2 fluorescence microscope and the IPLab Spectrum P software (Scanalytics Inc., Fairfax, VA, USA). A minimum of 50 interphases were analysed for each individual ovarian cell line.
Mutation analysis -RT-PCR
RT-PCR products were obtained from total RNA extracted from each sample (Table 2) using Trizol reagent (GibcoBRL, Rockville, MD, USA) following the manufacturer's instructions. For each reaction, DNA was eliminated by treating 5 mg of total RNA with RNase-free DNase for 30 min at 371C and the DNase inactivated by incubating the reaction for 10 min at 901C. Reverse transcription of DNase-treated RNA was performed following the manufacturer's protocol (GibcoBRL, Rockville, MD, USA).
Parkin-specific primers were designed to amplify exons 1-6 and 5-12 using the Oligo 6.4 software (Molecular Biology Insights) ( Table 1) . The PCR samples (20 ml total volume) contained 50-100 ng of reverse-transcribed cDNAs, 1 Â PCR buffer (as supplied with enzyme), 0.5 mM BSA, 200 mM dNTPs, 4 mM MgCl 2 , 750 mM forward and reverse primers for the specific genes, and 0.1 U Platinum Taq polymerase (Invitrogen, Carlsbad, CA, USA). The conditions for amplification were: 951C for 3 min, then 35 cycles of 951C for 30 s, 55-611C for 30 s, and 721C for 30 s with a final extension of 721C for 10 min. PCR reactions were electrophoresed on a 2.0% agarose gel. The PCR products were gel extracted using the QIAquick gel-extraction kit (Qiagen, Valencia, CA, USA) and sequenced by the Mayo Foundation Molecular Core Facility (Rochester, MN, USA).
Western blot analysis
For immunoblotting, proteins were extracted from normal OVSE, six ovarian tumor-derived cell lines (OV167, OV177, OV202, OV207, SKOV3, and OVCAR5), and seven primary ovarian tumors (OV470, endo, 3C; OV491, endo, 4; OV714, endo, 3C; OV854, serous, 1A; OV270, serous, 3C; OV111, endo, 3C; and OV465, endo, 3C). Tissue was incubated in lysis buffer (25 mM Tris-phosphate, 2 mM DTT, 2 mM diaminocyclohexane N,N,N 0 ,N 0 -tetraacetic acid, 10% glycerol, 1% Triton X-100, 5 mM PMSF) and homogenized using Dounce homogenizer. The supernatant was collected by centrifugation at 13 000 r.p.m., 10 min, 41C, and the protein concentration was determined using the Bradford assay. All cells were washed three times with DPBS and then lysed in buffer (same as above) for 5 min. After centrifugation for 10 min at 13 000 r.p.m., the supernatant was collected and the protein concentration was determined using the Bradford assay. Cell lysates (containing 50 mg of protein) were resolved on 10% SDS-PAGE and processed according to standard protocols. The antibodies used were a Parkin polyclonal antibody and a corresponding control actin antibody. The secondary antibodies (anti-rabbit or anti-mouse) conjugated to horseradish peroxidase (dilution 1 : 5000). Signals were detected using the ECL system (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Figure 3 FISH analysis of ovarian cell lines to determine the ratio of PARK2 to HBB. Probes for PARK2 (yellow), HBB (red), and the centromere of chromosome 6 (aqua) were hybridized to interphase chromosomes obtained from each cell line. Chromosomal interphases were counterstained with DAPI. All three possible ratios are represented in the figure: (a) 1 : 1 ratio of PARK2 to HBB (three yellow : three red); (b) o1 : 1 ratio of PARK2 to HBB (three yellow : two red); and (c) 41 : 1 ratio of PARK2 to HBB (three yellow : two red)
